All clinical conditions

Clinical condition

Atypical Depression

DSM-5 MDD with atypical features specifier

A depression subtype where mood brightens with good news, plus oversleeping, overeating, heaviness, and rejection sensitivity.

Common ways people search for this

atypical depression treatmentdepression but mood improves with good newsoversleeping depressionleaden paralysisrejection sensitive depression
The short version
  • Atypical depression is a depression subtype defined by mood reactivity — your mood can lift in response to positive events — plus features that are the "reverse" of classic depression.
  • Those features include oversleeping (hypersomnia), increased appetite or weight gain, a heavy "leaden" feeling in the limbs, and long-standing rejection sensitivity.
  • Despite the name, it's common — and it often starts earlier and runs more chronically than non-atypical depression.¹
  • Historically it was notable for responding better to MAOI antidepressants than to tricyclics; today SSRIs/SNRIs and therapy are first-line.²
  • When it becomes treatment-resistant, the same options as other depressions apply, including rapid-acting treatments like ketamine.
  • This page is educational, not a diagnosis. A clinician can confirm the pattern and tailor treatment.

Clinical definition

Atypical depression is a major depressive episode (or persistent depressive disorder) with the DSM-5 "atypical features" specifier: the defining feature is mood reactivity (mood brightens in response to actual or potential positive events), plus at least two of significant weight gain or appetite increase, hypersomnia, leaden paralysis (a heavy, weighted feeling in the arms or legs), and a long-standing pattern of interpersonal rejection sensitivity that causes impairment. It contrasts with "melancholic" depression, where mood is non-reactive and appetite and sleep decrease. Atypical features are common, tend toward earlier onset and a more chronic course, and have historically predicted a differential treatment response.

How it differs from related conditions

vs. Major depressive disorder

Atypical depression is MDD with the atypical-features specifier — the reactivity, oversleeping, and overeating distinguish it from classic (melancholic) presentations.

vs. Seasonal affective disorder

Winter SAD shares the atypical-like features (oversleeping, carb craving, heaviness) but is tied to seasonal timing.

vs. Bipolar 2 depression

Atypical features are common in bipolar depression too, so a careful history for hypomania matters before treatment.

First-line treatments

SSRIs / SNRIs

Modern first-line pharmacotherapy; effective for atypical depression and far better tolerated than older agents.

Psychotherapy (CBT)

Effective alone or with medication, and targets the rejection-sensitivity and reactivity patterns.

MAOIs in selected cases

Historically more effective than tricyclics for atypical depression; reserved for specialist use today.

Lifestyle and rhythm support

Addressing hypersomnia, activity, and routine supports recovery.

Evidence-based therapy guides

When standard treatments fail

When atypical depression doesn't respond to first-line antidepressants and therapy, the pathway mirrors treatment-resistant depression generally — switching or augmenting, MAOIs in specialist hands, and rapid-acting glutamatergic treatment such as ketamine or esketamine. A careful check for bipolarity is important first, since atypical features are common in bipolar depression.

Where ketamine fits

Atypical depression follows the same logic as depression generally: first-line is antidepressants and therapy, and ketamine enters the picture when the depression proves treatment-resistant. Ketamine's established efficacy in treatment-resistant depression applies here.³ One important caveat specific to atypical features: because they're also common in bipolar depression, a careful screen for hypomania comes first — if the picture is bipolar-spectrum, ketamine would only be used with mood-stabilizer cover. For a clearly unipolar, treatment-resistant atypical depression, ketamine is a reasonable option.

Where this fits with Tovani

Tovani treats depression, including atypical presentations, when it has proven resistant to first-line treatment. Because atypical features (oversleeping, overeating, rejection sensitivity, mood reactivity) overlap with bipolar depression, our screening for mood elevation and bipolar history matters before treatment. For a unipolar, treatment-resistant atypical depression, ketamine may be a fit alongside therapy; where the picture suggests bipolarity, that changes the approach.

Frequently asked

What makes depression "atypical"?

The defining feature is mood reactivity — your mood can lift with good news — plus features that reverse classic depression: oversleeping, increased appetite or weight gain, a heavy "leaden" feeling in the limbs, and long-standing rejection sensitivity. Despite the name, it's actually common.

How is atypical depression treated?

First-line today is SSRIs/SNRIs and psychotherapy (CBT). Historically it responded better to MAOI antidepressants than to tricyclics, and MAOIs are still used in selected, specialist cases. When it's treatment-resistant, the options match other depressions, including ketamine.

Is atypical depression related to bipolar disorder?

They can overlap — atypical features are common in bipolar depression. That's why a careful history for hypomania matters before starting treatment, because if the picture is bipolar-spectrum, antidepressants and ketamine need mood-stabilizer protection.

Can ketamine help atypical depression?

When it's a unipolar, treatment-resistant atypical depression, yes — ketamine's efficacy in treatment-resistant depression applies. The important first step is screening for bipolarity, since atypical features overlap with bipolar depression; if it's bipolar-spectrum, the approach changes.

References

  1. Stewart JW & McGrath PJ 1993, Psychiatric Clinics of North America Establishes atypical depression as a valid clinical entity with distinct features. (PMID 8415233)
  2. Quitkin FM & Stewart JW 1993, British Journal of Psychiatry (Suppl) Columbia atypical depression — a subgroup with better response to MAOIs than tricyclics. (PMID 8217065)
  3. Fava M et al. 2020, Molecular Psychiatry Dose-ranging trial establishing IV ketamine's efficacy in treatment-resistant depression. (PMID 30283029)

Last reviewed by Dr. Ben Soffer, DO on June 2, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.